Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hutchmed
Pharma
Roche-Innovent, AstraZeneca, Viatris and more—Fierce Pharma Asia
Roche and Ideaya separately licensed ADCs from Chinese firms. Experts weighed in on AZ's China probes. A Viatris plant got a warning letter. And more.
Angus Liu
Jan 3, 2025 8:37am
Hutchmed inks $608M asset sale to focus on ADC development
Jan 2, 2025 11:10am
Eli Lilly partner Hutchmed scraps stomach cancer filing
Aug 30, 2024 10:39am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia
Nov 10, 2023 8:05am
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Nov 9, 2023 10:54am
